CY1118561T1 - Λυοφιλιωμενη φαρμακοτεχνικη μορφη αριπιπραζολης - Google Patents
Λυοφιλιωμενη φαρμακοτεχνικη μορφη αριπιπραζοληςInfo
- Publication number
- CY1118561T1 CY1118561T1 CY20161101125T CY161101125T CY1118561T1 CY 1118561 T1 CY1118561 T1 CY 1118561T1 CY 20161101125 T CY20161101125 T CY 20161101125T CY 161101125 T CY161101125 T CY 161101125T CY 1118561 T1 CY1118561 T1 CY 1118561T1
- Authority
- CY
- Cyprus
- Prior art keywords
- aripiprazole
- aripiprazol
- pharmaceutical form
- lyophilized pharmaceutical
- lyophilized
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 6
- 229960004372 aripiprazole Drugs 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Ένα αντικείμενο της παρούσας εφεύρεσης είναι η παροχή μίας λυοφιλιωμένης φαρμακοτεχνικής μορφής αριπιπραζόλης σε σκόνη, που εμφανίζει καλή ικανότητα διασποράς και μπορεί εύκολα να διασπαρεί σ' ένα ομοιογενές εναιώρημα, όταν ανασυσταίνεται με νερό. Η παρούσα εφεύρεση παρέχει μία λυοφιλιωμένη φαρμακοτεχνική μορφή αριπιπραζόλης που προκύπτει από μία διαδικασία που περιλαμβάνει τα στάδια του ψεκασμού για ψύξη ενός εναιωρήματος αριπιπραζόλης που περιέχει (I) αριπιπραζόλη, (II) ένα όχημα για την αριπιπραζόλη, και (III) νερό για ένεση, και της ξήρανσης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161494088P | 2011-06-07 | 2011-06-07 | |
PCT/JP2012/065180 WO2012169662A1 (en) | 2011-06-07 | 2012-06-07 | Freeze-dried aripiprazole formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118561T1 true CY1118561T1 (el) | 2017-07-12 |
Family
ID=46420491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101125T CY1118561T1 (el) | 2011-06-07 | 2016-11-03 | Λυοφιλιωμενη φαρμακοτεχνικη μορφη αριπιπραζολης |
Country Status (30)
Country | Link |
---|---|
US (3) | US11154507B2 (el) |
EP (1) | EP2717859B1 (el) |
JP (1) | JP6012637B2 (el) |
KR (1) | KR102014124B1 (el) |
CN (3) | CN103596557A (el) |
AR (2) | AR086682A1 (el) |
AU (1) | AU2012267810B2 (el) |
BR (1) | BR112013031459B1 (el) |
CA (1) | CA2837693C (el) |
CO (1) | CO6842019A2 (el) |
CY (1) | CY1118561T1 (el) |
DK (1) | DK2717859T3 (el) |
EA (1) | EA023951B1 (el) |
ES (1) | ES2599479T3 (el) |
HK (1) | HK1191245A1 (el) |
HR (1) | HRP20161357T1 (el) |
HU (1) | HUE031723T2 (el) |
IL (1) | IL229467A (el) |
JO (1) | JO3410B1 (el) |
LT (1) | LT2717859T (el) |
MX (1) | MX354473B (el) |
MY (1) | MY166052A (el) |
PL (1) | PL2717859T3 (el) |
PT (1) | PT2717859T (el) |
SG (1) | SG195046A1 (el) |
SI (1) | SI2717859T1 (el) |
TW (1) | TWI519320B (el) |
UA (1) | UA112186C2 (el) |
WO (1) | WO2012169662A1 (el) |
ZA (1) | ZA201308868B (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
CN105663057A (zh) * | 2015-12-30 | 2016-06-15 | 中国药科大学 | 阿立哌唑长效混悬剂及其制备方法 |
WO2018020325A1 (en) | 2016-07-28 | 2018-02-01 | Mylan Laboratories Ltd, | Process for preparing sterile aripiprazole formulation |
CN115768407A (zh) * | 2020-05-21 | 2023-03-07 | 江苏先声药业有限公司 | 一种含依匹哌唑药物组合物及其制备方法 |
CN112656767A (zh) * | 2021-01-22 | 2021-04-16 | 烟台东诚药业集团股份有限公司 | 一种依诺肝素钠注射制剂及其制备方法 |
EP4043008A1 (en) | 2021-02-15 | 2022-08-17 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Method for the preparation of a pharmaceutical composition comprising aripiprazole |
CN118201600A (zh) * | 2021-11-10 | 2024-06-14 | 广东东阳光药业股份有限公司 | 一种喹啉类药物的组合物 |
GR1010656B (el) * | 2023-03-23 | 2024-03-21 | Φαρματεν Α.Β.Ε.Ε., | Φαρμακευτικο σκευασμα που περιλαμβανει εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
GB9105705D0 (en) | 1991-03-18 | 1991-05-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
GB9718986D0 (en) | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
MY129350A (en) | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
US20050019607A1 (en) | 2003-06-30 | 2005-01-27 | Franky So | OLED device with mixed emissive layer |
US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
ES2315721T5 (es) * | 2003-10-23 | 2012-08-24 | Otsuka Pharmaceutical Co., Ltd. | Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento |
EP1732107A4 (en) | 2004-03-30 | 2009-05-13 | Fujitsu Microelectronics Ltd | METHOD FOR CORRECTING EXPOSURE DATA TO AN ELECTRON BEAM |
US7731873B2 (en) | 2005-08-09 | 2010-06-08 | Coopervision International Holding Company, Lp | Contact lens mold assemblies and systems and methods of producing same |
EP1933814A2 (en) * | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
UA97286C2 (ru) | 2007-07-31 | 2012-01-25 | Оцука Фармасьютикал Ко., Лтд. | Способ изготовления суспензии арипипразола и лиофилизированного состава |
-
2012
- 2012-06-03 JO JOP/2012/0141A patent/JO3410B1/ar active
- 2012-06-06 AR ARP120101990A patent/AR086682A1/es not_active Application Discontinuation
- 2012-06-06 TW TW101120275A patent/TWI519320B/zh active
- 2012-06-07 CN CN201280027909.5A patent/CN103596557A/zh active Pending
- 2012-06-07 JP JP2013554727A patent/JP6012637B2/ja active Active
- 2012-06-07 LT LTEP12731189.2T patent/LT2717859T/lt unknown
- 2012-06-07 CN CN201810450421.2A patent/CN108379231A/zh active Pending
- 2012-06-07 HU HUE12731189A patent/HUE031723T2/hu unknown
- 2012-06-07 EA EA201391818A patent/EA023951B1/ru not_active IP Right Cessation
- 2012-06-07 CA CA2837693A patent/CA2837693C/en active Active
- 2012-06-07 WO PCT/JP2012/065180 patent/WO2012169662A1/en active Application Filing
- 2012-06-07 KR KR1020147000021A patent/KR102014124B1/ko active IP Right Grant
- 2012-06-07 ES ES12731189.2T patent/ES2599479T3/es active Active
- 2012-06-07 US US14/124,459 patent/US11154507B2/en active Active
- 2012-06-07 SG SG2013085568A patent/SG195046A1/en unknown
- 2012-06-07 MX MX2013014186A patent/MX354473B/es active IP Right Grant
- 2012-06-07 AU AU2012267810A patent/AU2012267810B2/en active Active
- 2012-06-07 PT PT127311892T patent/PT2717859T/pt unknown
- 2012-06-07 CN CN201610937357.1A patent/CN106389357A/zh active Pending
- 2012-06-07 MY MYPI2013702194A patent/MY166052A/en unknown
- 2012-06-07 DK DK12731189.2T patent/DK2717859T3/en active
- 2012-06-07 BR BR112013031459-1A patent/BR112013031459B1/pt active IP Right Grant
- 2012-06-07 EP EP12731189.2A patent/EP2717859B1/en active Active
- 2012-06-07 PL PL12731189T patent/PL2717859T3/pl unknown
- 2012-06-07 SI SI201230741A patent/SI2717859T1/sl unknown
- 2012-07-06 UA UAA201315553A patent/UA112186C2/uk unknown
-
2013
- 2013-11-17 IL IL229467A patent/IL229467A/en active IP Right Grant
- 2013-11-19 ZA ZA2013/08868A patent/ZA201308868B/en unknown
- 2013-12-30 CO CO13302836A patent/CO6842019A2/es unknown
-
2014
- 2014-05-14 HK HK14104543.8A patent/HK1191245A1/zh unknown
-
2016
- 2016-10-18 HR HRP20161357TT patent/HRP20161357T1/hr unknown
- 2016-11-03 CY CY20161101125T patent/CY1118561T1/el unknown
-
2021
- 2021-09-24 US US17/448,862 patent/US20220008341A1/en not_active Abandoned
- 2021-11-29 AR ARP210103281A patent/AR124163A2/es unknown
-
2023
- 2023-10-09 US US18/483,098 patent/US20240041774A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118561T1 (el) | Λυοφιλιωμενη φαρμακοτεχνικη μορφη αριπιπραζολης | |
CY1124011T1 (el) | Συνθεσεις γλυκοπεπτιδιου | |
CY1120507T1 (el) | Συνεργιστικη ενισχυση της διανομης νουκλεϊκων οξεων μεσω συμμειγμενων σκευασματων | |
GEP20186852B (en) | Compositions comprising short-acting benzodiazepines | |
BR112016002399A2 (pt) | compostos e métodos para a modulação da expressão da distrofia miotônica-proteína quinase (dmpk) | |
BR112015023168A2 (pt) | composições de dicetopiperazina microcristalina e métodos | |
CY1118899T1 (el) | Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων | |
BR112017002301A2 (pt) | encapsulação de compostos hidrofóbicos biologicamente ativos | |
DOP2015000022A (es) | 2,3-benzodiacepinas | |
MY184628A (en) | Afucosylated anti-fgfr2iiib antibodies | |
PE20142338A1 (es) | Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf | |
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
CY1121829T1 (el) | Κατιονικα πολυμερη που εχουν τη βαση τους στο γλυκογονο | |
BR112016025016A2 (pt) | composições de proteína de partículas pequenas e métodos de produção | |
PH12015502146A1 (en) | 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides | |
TWD170386S (zh) | 電連接器之部分 | |
NZ730790A (en) | Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof | |
CY1120820T1 (el) | Νεα συνθεση αλβαιντανυλης για την αγωγη του οξεος πονου | |
BR112018076389A2 (pt) | composto, método para preparação de um composto, e, composição farmacêutica. | |
MX2015015953A (es) | Composicion que comprende una combinacion de un polimero acrilico y una silicona amino. | |
BR112016001539A8 (pt) | formulações em pó aperfeiçoadas de ácidos orgânicos ou ésteres tendo um sistema de anel aromático | |
UA115072C2 (uk) | Похідні гідантоїну | |
BR112015024877A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose | |
EA201500942A1 (ru) | ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН | |
CY1122099T1 (el) | Αλατα ναλμεφενης ως φαρμακα για τη μειωση της καταναλωσης αλκοολ ή για την προληψη της υπερβολικης καταναλωσης αλκοολ |